ANTI-TUMOR ACTIVITY OF BENZALDEHYDE

Google Scholar
  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (1) , 21-23
Abstract
Patients (90) with inoperable carcinoma in the terminal stages and 12 patients in serious condition with other tumor types were given benzaldehyde in the form of .beta.-cyclodextrin benzaldehyde inclusion compound (CDBA) orally or rectally at a daily dose of 10 mg/kg divided in 4 doses. Toxic effects, including hematologic or biochemical disturbances, were not seen during long-term successive administration of CDBA. Of the patients treated, 57 were evaluable; 19 patients responded completely and 10 patients responded partially (> 50% regression). For all responding patients longer response durations were associated with longer CDBA treatment periods. Treatment of squamous cell carcinoma induced the cancer cells to change into a conglomeration of pearls (the well-known product of differentiation) which consisted of keratinized normal squamous cells.

This publication has 1 reference indexed in Scilit: